Magnolia Capital Advisors’s Gilead Sciences GILD Stock Holding History

Magnolia Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$463K	Buy	3,320 +34	+1%	+$4.76K	0.09%	209
2025 Q4	$403K	Buy	3,286 +190	+6%	+$23.1K	0.08%	203
2025 Q3	$344K	Buy	3,096 +29	+0.9%	+$3.3K	0.09%	183
2025 Q2	$340K	Buy	3,067 +33	+1%	+$3.51K	0.09%	188
2025 Q1	$340K	Sell	3,034 -223	-7%	-$23K	0.09%	181
2024 Q4	$301K	Buy	+3,257	New	+$293K	0.08%	194
2022 Q2	–	Sell	-3,481	Closed	-$207K	–	150
2022 Q1	$207K	Buy	3,481 +241	+7%	+$15.4K	0.08%	177
2021 Q4	$235K	Buy	+3,240	New	+$223K	0.07%	176

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Magnolia Capital Advisors's GILD Position: Q1 2026 in Review

Magnolia Capital Advisors increased its Gilead Sciences (GILD) stake by 1% in Q1 2026, buying an estimated $4.76K and bringing the position to 3,320 shares worth $463K. The position accounts for 0.09% of the portfolio, ranked #209.

Magnolia Capital Advisors first reported a position in GILD in Q4 2021 and has held it in 8 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Magnolia Capital Advisors held 3,320 shares of Gilead Sciences worth $463K as of Q1 2026.
Magnolia Capital Advisors bought 34 Gilead Sciences shares in Q1 2026, an estimated $4.76K.
Gilead Sciences made up 0.09% of Magnolia Capital Advisors's portfolio in Q1 2026, its #209 holding.
Magnolia Capital Advisors first reported a position in Gilead Sciences in Q4 2021 and has held it in 8 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Magnolia Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.